Oga A, Kong G, Tae K, Lee Y, Sasaki K
Department of Pathology, Yamaguchi University School of Medicine, Minami Kogushi 1-1-1, Ube-shi 755-8505, Yamaguchi, Japan.
Cancer Genet Cytogenet. 2001 May;127(1):24-9. doi: 10.1016/s0165-4608(00)00430-1.
We analyzed DNA sequence copy number aberrations (DSCNAs) in 17 primary oral squamous cell carcinomas (OSCCs) by comparative genomic hybridization. DSCNAs were detected frequently at 3q25-qter (7/17), Xp21 (5/17), and Xq12-q23 and 8q23-q24 (4/17), and losses were detected frequently at 13q21-q22 (5/17), 3p21-pter, 4p15-pter and 17p13 (4/17), and 8p22-pter and 9p21-pter (3/17). Four tumors showed amplifications of seven loci: 3q11-qter, 3q13, 3q26, 7q21-q22, 8q23-qter, 9p22-pter, and 12p11. The total number of DSCNAs was significantly greater in stage III and stage IV tumors than in stage I and stage II tumors (P=.008). Furthermore, 3q gain was detected preferentially in stage III and stage IV tumors (6/8) rather than in stage I and stage II tumors (1/9, P=.013). In our study, all tumors with gain of 3q also contained one or more loss(es) in common regions. On the other hand, all tumors with gain of 9p did not contain 3q gains. These observations indicate that gain of 3q and accumulation of DSCNAs are strongly associated with tumor progression in OSCC. Furthermore, 3q gain and loss of one or more additional loci in common aberration regions appears to be a group of DSCNs associated with dominant genetic pathways of leading to advanced OSCCs.
我们通过比较基因组杂交分析了17例原发性口腔鳞状细胞癌(OSCC)中的DNA序列拷贝数畸变(DSCNA)。DSCNA在3q25 - qter(7/17)、Xp21(5/17)以及Xq12 - q23和8q23 - q24(4/17)区域频繁检测到,而缺失则在13q21 - q22(5/17)、3p21 - pter、4p15 - pter和17p13(4/17)以及8p22 - pter和9p21 - pter(3/17)区域频繁检测到。4例肿瘤显示7个位点扩增:3q11 - qter、3q13、3q26、7q21 - q22、8q23 - qter、9p22 - pter和12p11。III期和IV期肿瘤中的DSCNA总数显著多于I期和II期肿瘤(P = 0.008)。此外,3q增益在III期和IV期肿瘤中更易检测到(6/8),而在I期和II期肿瘤中较少(1/9,P = 0.013)。在我们的研究中所有3q增益的肿瘤在共同区域也包含一个或多个缺失。另一方面,所有9p增益的肿瘤均不包含3q增益。这些观察结果表明3q增益和DSCNA积累与OSCC的肿瘤进展密切相关。此外,3q增益以及共同畸变区域中一个或多个其他位点的缺失似乎是一组与导致晚期OSCC的主要遗传途径相关的DSCN。